Robocath said today that it completed its first two coronary angioplasties performed with its R-One robotic platform.
Both procedures were performed in France, as Drs. Eric Durand and Rémi Sabatier oversaw one at Rouen University Hospital and Dr. Jean Fajadet performed one at Clinique Pasteur in Toulouse.
The R-One system is designed to facilitate and enhance interventional procedures, such as coronary angioplasty, “offering a better working environment for physicians and the entire medical team,” according to Robocath.
The Rouen, France-based company said the prospective clinical study is the first of its kind conducted in Europe. It includes six European sites and 60 patients with the goal of demonstrating the safety and efficacy of the R-One in coronary angioplasties.
The R-One device won CE Mark approval in February and pulled in $5.5 million earlier this month, which it earmarked for the R-One platform. In May 2017, Robocath landed $5.2 million in one funding round, before adding $2 million just more than six months later.
“These two successes mark a new era in the way interventional cardiology is practiced in Europe today,” president & founder Dr. Philippe Bencteux said in prepared remarks. “It is a project we have worked on for several years and the entire team and I are extremely proud of the success of these two procedures.”
“I feel particularly privileged to have been given the opportunity several years ago to participate in this project and to now arrive at this first procedure in a human with excellent results,” added Durand.
“It is a French success story that has been supported by all of our employees and by highly invested medical and technical teams, to whom I would today like to extend my warmest thanks and congratulations,” Robocath’s recently-appointed CEO Lucien Goffart said. “It is a crucial step in our development and one that will pave the way for a transformation of the sector. This transformation involves all of the players in the industry and inevitably leads us to think about this industry in broader terms, thanks to the new possibilities offered by robotics, particularly in terms of the interoperability of equipment.”
Original Article: (https://www.massdevice.com/robocath-touts-r-one-coronary-angioplasty-platform/)